Clinical and cost outcomes following genomics‐informed treatment for advanced cancers-Reference-Cited by-同舟云学术

Clinical and cost outcomes following genomics‐informed treatment for advanced cancers

Published:2021-06-21 Issue:15 Volume:10 Page:5131-5140
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Weymann Deirdre¹^ORCID,Pollard Samantha¹²,Chan Brandon¹,Titmuss Emma³,Bohm Alexandra³,Laskin Janessa⁴⁵,Jones Steven J. M.³⁶,Pleasance Erin³,Nelson Jessica³,Fok Alexandra³,Lim Howard⁴⁵,Karsan Aly³⁴⁷,Renouf Daniel J.⁴⁵,Schrader Kasmintan A.⁶⁸⁹,Sun Sophie⁴⁵,Yip Stephen⁷¹⁰,Schaeffer David F.¹¹,Marra Marco A.³⁶,Regier Dean A.¹²

Affiliation:

1. Cancer Control ResearchBC Cancer Vancouver Canada

2. School of Population and Public Health University of British Columbia Vancouver Canada

3. Canada's Michael Smith Genome Sciences Centre BC Cancer Vancouver Canada

4. Division of Medical Oncology BC Cancer Vancouver Canada

5. Department of Medicine Faculty of Medicine University of British Columbia Vancouver Canada

6. Department of Medical Genetics Faculty of Medicine University of British Columbia Vancouver Canada

7. Department of Pathology & Laboratory Medicine Faculty of Medicine University of British Columbia Vancouver Canada

8. Department of Molecular Oncology BC Cancer Vancouver Canada

9. Hereditary Cancer Program BC Cancer Vancouver Canada

10. Department of Pathology BC Cancer Vancouver Canada

11. Division of Anatomical Pathology Vancouver General HospitalUniversity of British Columbia Vancouver Canada

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4076

Reference35 articles.

1. The current state of implementation science in genomic medicine: opportunities for improvement

2. Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation

3. Economic Evaluations of Next-Generation Precision Oncology: A Critical Review

4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

5. Precision medicine: lessons learned from the SHIVA trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review;Critical Reviews in Oncology/Hematology;2024-10

2. Precision Medicine;Therapeutic Strategies in Veterinary Oncology;2023-08-23

3. Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma;Therapeutic Advances in Medical Oncology;2023-01

4. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma;Nature Communications;2022-10-08

5. Whole-genome and transcriptome analysis enhances precision cancer treatment options;Annals of Oncology;2022-09